Tg Therapeutics (TGTX) Enterprise Value (2011 - 2026)

Tg Therapeutics' Enterprise Value history runs 16 years deep, the most recent figure standing at -$645.0 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 133.5% year-over-year to -$645.0 million; the TTM figure through Mar 2026 stood at -$645.0 million (down 133.5% YoY), while the FY2025 annual figure was -$64.1 million, up 51.21% from the prior year.
• Enterprise Value was -$645.0 million for Q1 2026 at Tg Therapeutics, down from -$64.1 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$64.1 million in Q4 2025 to a low of -$645.0 million in Q1 2026.
• Historically, Enterprise Value has averaged -$214.0 million across 5 years, with a median of -$195.7 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Enterprise Value surged 61.42% in 2025, then sank 133.5% in 2026.
• A 5-year view of Enterprise Value shows it stood at -$161.7 million in 2022, then sank by 34.53% to -$217.5 million in 2023, then surged by 39.55% to -$131.5 million in 2024, then jumped by 51.21% to -$64.1 million in 2025, then sank by 905.57% to -$645.0 million in 2026.
• The last three Enterprise Value figures came in at -$645.0 million (Q1 2026), -$64.1 million (Q4 2025), and -$131.6 million (Q3 2025), per Business Quant data.